Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor
Journal Article (Review;Journal)
Clinical Development Phases I-III Regulatory, Quality, Manufacturing Thrombosis as a clinical phenotype is ubiquitous in human diseases and conditions, ranging from atherosclerosis and other vascular disorders to trauma, surgery, malignancy, infections, blood dyscrasias, auto-immunity, and complications of pregnancy. While each condition carries its own distinct signature and predisposition for thrombosis as a nonphysiological event, there are several common themes that center on cellular and noncellular elements, including well-characterized coagulation proteases. Over the past decade, our group has been actively involved with the development of a factor IXa inhibitor, pegnivacogin, and its complementary antidote or control agent, anivamersen. The following review provides a summary of fundamental constructs, milestones, and the current status of our translational journey. © 2013 Wiley Periodicals, Inc.
Full Text
Duke Authors
Cited Authors
- Becker, RC; Chan, MY; Vavalle, JP; Povsic, TJ
Published Date
- December 1, 2013
Published In
Volume / Issue
- 74 / 8
Start / End Page
- 510 - 516
Electronic International Standard Serial Number (EISSN)
- 1098-2299
International Standard Serial Number (ISSN)
- 0272-4391
Digital Object Identifier (DOI)
- 10.1002/ddr.21109
Citation Source
- Scopus